These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 28183250)

  • 61. Epidermal growth factor receptor tyrosine kinase inhibitors: present and future role in gastrointestinal cancer treatment: a review.
    Arnold D; Peinert S; Voigt W; Schmoll HJ
    Oncologist; 2006 Jun; 11(6):602-11. PubMed ID: 16794239
    [TBL] [Abstract][Full Text] [Related]  

  • 62. The Real Impact of Target Therapy in Breast Cancer Patients: Between Hope and Reality.
    Bordonaro S; Berretta M; Tralongo AC; Clementi S; Stanzione B; Tralongo P
    Curr Cancer Drug Targets; 2018; 18(5):480-498. PubMed ID: 28183251
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Cyclooxygenase-2 in tumorigenesis of gastrointestinal cancers: an update on the molecular mechanisms.
    Wu WK; Sung JJ; Lee CW; Yu J; Cho CH
    Cancer Lett; 2010 Sep; 295(1):7-16. PubMed ID: 20381235
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Targeting platelet-derived growth factor (PDGF) signaling in gastrointestinal cancers: preclinical and clinical considerations.
    Abdel-Rahman O
    Tumour Biol; 2015 Jan; 36(1):21-31. PubMed ID: 25394897
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Molecular profiles in foregut oncology.
    Sukharamwala P; Hennessey D; Wood T; Singh S; Ryan C; Rosemurgy A
    Cancer Genet; 2016 Dec; 209(12):537-553. PubMed ID: 27887938
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Current drugs and drug targets in non-small cell lung cancer: limitations and opportunities.
    Daga A; Ansari A; Patel S; Mirza S; Rawal R; Umrania V
    Asian Pac J Cancer Prev; 2015; 16(10):4147-56. PubMed ID: 26028064
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Antibody-drug conjugate directed against the guanylyl cyclase antigen for the treatment of gastrointestinal malignancies.
    Almhanna K; Prithviraj GK; Veiby P; Kalebic T
    Pharmacol Ther; 2017 Feb; 170():8-13. PubMed ID: 27765652
    [TBL] [Abstract][Full Text] [Related]  

  • 68. [Improving the internal medical care to set up a leading model for precision medicine development in lung cancer].
    Han BH
    Zhonghua Zhong Liu Za Zhi; 2017 Feb; 39(2):81-85. PubMed ID: 28219199
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Emerging tyrosine kinase inhibitors for the treatment of metastatic colorectal cancer.
    Matos I; Elez E; Capdevila J; Tabernero J
    Expert Opin Emerg Drugs; 2016 Sep; 21(3):267-82. PubMed ID: 27578253
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Management of advanced non-small cell lung cancers with known mutations or rearrangements: latest evidence and treatment approaches.
    Shea M; Costa DB; Rangachari D
    Ther Adv Respir Dis; 2016 Apr; 10(2):113-29. PubMed ID: 26620497
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Expression and Single Nucleotide Polymorphism of Poly (ADPRibose) Polymerase-1 in Gastrointestinal Tumours: Clinical Involvement.
    Martín-Guerrero SM; León J; Quiles-Perez R; Belmonte L; Martin-Oliva D; Ruiz-Extremera Á; Salmerón J; Muñoz-Gámez JA
    Curr Med Chem; 2017; 24(20):2156-2173. PubMed ID: 28302009
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Anti-metastatic treatment in colorectal cancer: targeting signaling pathways.
    Lemos C; Sack U; Schmid F; Juneja M; Stein U
    Curr Pharm Des; 2013; 19(5):841-63. PubMed ID: 22973955
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Selective PI3K inhibition by BKM120 and BEZ235 alone or in combination with chemotherapy in wild-type and mutated human gastrointestinal cancer cell lines.
    Mueller A; Bachmann E; Linnig M; Khillimberger K; Schimanski CC; Galle PR; Moehler M
    Cancer Chemother Pharmacol; 2012 Jun; 69(6):1601-15. PubMed ID: 22543857
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Translational challenges from the 2014 Gastrointestinal Cancers Symposium: toward a true tailored therapy through effective research.
    Aprile G; Giuliani F; Cordio S; Sartore-Bianchi A; Bencardino K; Ongaro E; Martines C; Giampieri R; Bordonaro R; Siena S; Cascinu S; Scartozzi M
    Future Oncol; 2014 May; 10(7):1125-8. PubMed ID: 24947252
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Epidermal growth factor receptor: pathway, therapies, and pipeline.
    Goffin JR; Zbuk K
    Clin Ther; 2013 Sep; 35(9):1282-303. PubMed ID: 24054705
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Targeting cyclin-dependent kinases in gastrointestinal cancer therapy.
    Zhang J; Su G; Lin Y; Meng W; Lai JKL; Qiao L; Li X; Xie X
    Discov Med; 2019 Jan; 27(146):27-36. PubMed ID: 30721649
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Therapeutic targeting of inflammation and tryptophan metabolism in colon and gastrointestinal cancer.
    Santhanam S; Alvarado DM; Ciorba MA
    Transl Res; 2016 Jan; 167(1):67-79. PubMed ID: 26297050
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Gastrointestinal cancer: towards a tailored tumour therapy.
    Seufferlein T; Adler G
    Scand J Gastroenterol Suppl; 2003; (237):22-5. PubMed ID: 12797676
    [TBL] [Abstract][Full Text] [Related]  

  • 79. EGFR(s) in aging and carcinogenesis of the gastrointestinal tract.
    Nautiyal J; Kanwar SS; Majumdar AP
    Curr Protein Pept Sci; 2010 Sep; 11(6):436-50. PubMed ID: 20491625
    [TBL] [Abstract][Full Text] [Related]  

  • 80. From conventional chemotherapy to targeted therapy: use of monoclonal antibodies (moAbs) in gastrointestinal (GI) tumors.
    Zoratto F; Rossi L; Giordani E; Strudel M; Papa A; Tomao S
    Tumour Biol; 2014 Sep; 35(9):8471-82. PubMed ID: 25062724
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.